News
-
-
COMMUNIQUÉ DE PRESSE
FSD Pharma Receives Ethics Committee Approval for a Phase-1 Multiple Ascending Doses Clinical Trial for Lucid-21-302 (Lucid-MS) in Australia
FSD Pharma announces HREC approval for Lucid-21-302 trial in Australia. Lucid-21-302 is a neuroprotective compound for multiple sclerosis treatment -
-
-
COMMUNIQUÉ DE PRESSE
FSD Pharma Enters Into an Exclusive Option Agreement With the University of Southern California To Evaluate Novel Dietary Supplement Technology for unbuzzd(TM) and Other Business Applications
FSD Pharma Inc. enters into an exclusive option agreement with the University of Southern California to evaluate dietary supplement technology for commercialization, potentially enhancing unbuzzd™ effectiveness and expanding target markets with novel products -
-
-
COMMUNIQUÉ DE PRESSE
FSD Pharma Receives Institutional Review Board Approval to Study the Safety and Efficacy of Unbuzzd(TM) in Acute Alcohol Intoxication
FSD Pharma obtains IRB approval in the USA for the METAL-2 trial, allowing recruitment of clinical trial participants for alcohol intoxication research -
-
